About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Massachusetts | 363 Studies

Clinical Trials MelanomaMassachusetts

Melanoma Clinical Trials in Massachusetts

Find 363 clinical trials for melanoma near Massachusetts. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 121-140 of 363 trials

Active not recruitingA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsThis is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or…NCT02988960·Los Angeles, California and 21 others CompletedCarboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant MelanomaThis randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant…NCT00976573·Scottsdale, Arizona and 309 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaThe purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.NCT05002569·Birmingham, Alabama and 183 others

Active not recruitingTesting Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadThis phase II trial compares the effect of dabrafenib and trametinib given continuously to given with a break in treatment (intermittent) in treating patients with stage III-IV…NCT02196181·Birmingham, Alabama and 751 others

CompletedNilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaGiven the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of…NCT00788775·Santa Monica, California and 7 others

TerminatedA Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTo characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.NCT02974725·San Diego, California and 31 others

TerminatedSafety Study of MGD009 in B7-H3-expressing TumorsThe purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors.NCT02628535·Los Angeles, California and 19 others

Active not recruitingA Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaThis is a Phase II, open-label, single arm study.NCT03999749·Los Angeles, California and 3 others

UnknownSafety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced MalignanciesThe primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies…NCT04137900·Birmingham, Alabama and 23 others

Active not recruitingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersTTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy…NCT04485013·Tucson, Arizona and 40 others

RecruitingPhase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsThis is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant…NCT05280314·New Haven, Connecticut and 14 others

CompletedNAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated…NCT05340621·Phoenix, Arizona and 11 others

TerminatedStudy of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayThis is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers.NCT06287463·Los Angeles, California and 8 others

CompletedClinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaThe purpose of this study is to test whether it is safe to give phenformin with the standard drug combination of one of 3 FDA-approved combinations of BRAF inhibitor + MEK…NCT03026517·Boston, Massachusetts and 2 others

TerminatedSafety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) MalignancyThe goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors.NCT00629187·Boston, Massachusetts

TerminatedStudy of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in…NCT04348916·Duarte, California and 10 others

CompletedNivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasThis phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid…NCT02304458·Birmingham, Alabama and 24 others

TerminatedCabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryThis phase I trial studies the side effects and best dose of cabozantinib-s-malate when given together with vemurafenib in treating patients with solid tumors or melanoma that is…NCT01835184·Atlanta, Georgia and 2 others

CompletedTreatment for Subjects With Unresectable Stage III or Stage IV MelanomaThis is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the…NCT00110994·Tucson, Arizona and 13 others

CompletedA Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine…NCT01721746·Phoenix, Arizona and 94 others

PreviousPage 7 of 19Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma